Clinical trials: Clopidogrel, completed
Healthy
Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects
The objectives of the study are to: Assess the within-subject variability of the pharmacokinetic profiles of the clopidogrel and its active metabolite after a replicated single administration of 75 mg of clopidogrel in healthy…
- Trial name
- NCT01129063
- Testing
- Clopidogrel
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acute Coronary Syndrome, Platelet Function
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis
Introduction: Platelet aggregation plays an important role in ischemic complications in patients undergoing to percutaneous coronary intervention (PCI).
- Trial name
- SAMPA (NCT02215993)
- Testing
- Prasugrel, Ticagrelor
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Federal University of São Paulo
Coronary Artery Disease
Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI.
- Trial name
- NCT00257751
- Testing
- Aprotinine
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Ischemic Stroke
China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis
Patients with symptomatic stenosis of intradural arteries are at high risk for subsequent stroke. Since the SAMMPRIS trial, stenting is no longer recommended as primary treatment, however, the results of this trial, its inclusion…
- Trial name
- CASSISS (NCT01763320)
- Testing
- Intracranial stenting group, medical group
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Xuanwu Hospital, Beijing
Stroke, Transient Ischemic Attack
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
The primary objective is to determine if patent foramen ovale (PFO) closure with the GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder plus antiplatelet medical management is safe and effective and reduces the risk…
- Trial name
- REDUCE (NCT00738894)
- Testing
- Septal Occluder Device, Antiplatelet Medical Therapy
- Where
- 2 sites in United States, Denmark
- Volunteers
- 664 people
- Sponsor
- W.L.Gore & Associates
Healthy
Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants
This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and clopidogrel in healthy male volunteers.
- Trial name
- NCT03814642
- Testing
- Clopidogrel 75 mg, Tegoprazan 50 mg, Esomeprazole 20 mg
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Ischemic Stroke, Acute
Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III
The trial is a phase 3, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled design. Patients with acute ischemic stroke due to anterior circulation large vessel occlusion within 4.5-24 hours from…
- Trial name
- TRACE III (NCT05141305)
- Testing
- tenecteplase (0.25 mg/kg, Max 25 mg), standard medical treatment
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Beijing Tiantan Hospital
STEMI, Chest Pain
Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial
The investigators propose to test the effectiveness of a technique that uses a modified commercially available ultrasound system used for cardiac imaging, and a commercially available ultrasound contrast agent (microbubbles) to…
- Trial name
- MRUSMI (NCT02170103)
- Testing
- percutaneous intervention (PCI), Microbubbles, Ultrasound
- Where
- 2 sites in Brazil, Netherlands
- Volunteers
- 50 people
- Sponsor
- University of Nebraska
Acute Coronary Syndrome
Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)
This study demonstrates the effect of generic clopidogrel bisulfate (Plavitor®) in comparison with the original clopidogrel bisulfate (Plavix®) in patients with acute coronary syndrome.
- Trial name
- NCT02060786
- Testing
- generic clopidogrel (Plavitor® ), original clopidogrel (Plavix® )
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Ajou University School of Medicine
Type 2 Diabetes Mellitus, Acute Coronary Syndrome
Assessment of Thrombogenicity in Acute Coronary Syndrome
The purpose of this study is to assess platelet dependent thrombogenicity in patients after acute coronary syndrome using an ex vivo arterial injury model.
- Trial name
- NCT00728286
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese…
- Trial name
- NCT01294462
- Testing
- Ticagrelor, Clopidogrel, Acetylsalicylic acid ASA
- Where
- 87 sites in Japan, South Korea and 1 more
- Volunteers
- 801 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart…
- Trial name
- NCT00402597
- Testing
- Rivaroxaban
- Volunteers
- 3,490 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.